RxDoctor Payments Data

Douglas Halliday, MD

Otolaryngology/Facial Plastic Surgery · Skaneateles, NYNPI 1255343984

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Merz North America, Inc. at 26.4% of the total.

$2,776in general payments, 2019–2025

Across 81 payments — averaging $34.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$732
  • Aerin Medical Inc.$640
  • Intersect ENT, Inc.$603
  • Optinose US, Inc.$183
  • Alk-abello, Inc$182
  • Sanofi$86
  • plus $349 from 8 others

What the payments were for

  • Food & beverage$2,776100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,776 in reported general payments places this provider in the 60th percentile of 48 otolaryngology/facial plastic surgery providers in New York.

See all otolaryngology/facial plastic surgery providers in New York

Medicare billing

Part B allowed, 2024
$96,279
Medicare patients
152
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate43$32,636
OdactraMite,d.Farinae-D.Pteronyssinus12$8,898
Azelastine Hcl22$714
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$442
Betamethasone Dipropionate13$332
Fluticasone Propionate17$202
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$163
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$162
Methylprednisolone25$159
Ipratropium Bromide14$152
Clindamycin Hcl26$152
Clotrimazole12$110
Cephalexin19$66
Azithromycin25$57
Levocetirizine Dihydrochloride13$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$183$32,63643 claims
Alk-abello, IncOdactra$182$8,89812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 otolaryngology/facial plastic surgery providers in New York.

Other otolaryngology/facial plastic surgery in Skaneateles

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →